Form 4: Allogene SVP Finance Reports Routine Equity Transactions

Allogene Therapeutics' SVP of Finance, Annie Yoshiyama, reported a 'sell to cover' transaction and received new equity grants.

Summary

• Annie Yoshiyama, SVP, Finance at Allogene Therapeutics, Inc. (ALLO), reported transactions on February 2, 2026.
• Sold 4,167 shares of common stock at a weighted average price of $1.72 per share (ranging from $1.71 to $1.74) to cover tax withholding obligations related to restricted stock unit vesting. This was a non-discretionary 'sell to cover' transaction.
• Acquired 179,691 stock options with an exercise price of $1.87, which will vest 25% on February 2, 2027, and the remainder in 36 equal monthly installments thereafter, expiring on February 2, 2036.
• Received an award of 50,827 Restricted Stock Units (RSUs), which will vest in four successive equal annual installments over a four-year period from February 2, 2026, contingent on continued service.
• Following these transactions, the reporting person beneficially owns 130,322 shares of common stock, 179,691 stock options, and 50,827 RSUs.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as largely neutral, reflecting routine executive compensation and tax-related transactions. The new equity grants are a positive for long-term incentive alignment, while the 'sell to cover' sale is a standard, non-discretionary event.

Positives

• Grant of 179,691 stock options, aligning management incentives with long-term company performance.
• Grant of 50,827 Restricted Stock Units (RSUs), further aligning management incentives with shareholder value creation and promoting retention.

Negatives

• Sale of 4,167 shares of common stock, although non-discretionary for tax purposes, reduces direct share ownership.

Future Outlook

The vesting schedules for the newly granted stock options and Restricted Stock Units (RSUs) extend through February 2, 2036, and February 2, 2030 (4 years from 2026), respectively, indicating a long-term incentive structure for the SVP of Finance, contingent on continued service.

Industry Context

StockSavvy.ai notes that equity grants to senior executives like an SVP of Finance are standard practice in the biotechnology and pharmaceutical industries, particularly for companies like Allogene Therapeutics, which are often in development stages. These grants are crucial for attracting and retaining talent, aligning executive interests with long-term shareholder value, and compensating for the inherent risks and long development cycles in the sector. The 'sell to cover' transaction is also a common, non-discretionary event for executives to meet tax obligations upon RSU vesting.

Comparison to Industry Standards

• StockSavvy.ai observes that the structure of equity compensation, including a mix of stock options and restricted stock units with multi-year vesting schedules, is consistent with compensation practices at comparable biotechnology firms.
• For instance, companies like CRISPR Therapeutics (CRSP) or Editas Medicine (EDIT) often utilize similar long-term incentive plans to retain key personnel and incentivize performance over extended periods, reflecting the lengthy R&D timelines in gene editing and cell therapy.

Stakeholder Impact

• Shareholders: The new equity grants align the SVP of Finance's interests with long-term shareholder value. The 'sell to cover' transaction has a minimal dilutive effect and is a standard practice.
• Employees: The equity grants demonstrate the company's commitment to executive compensation and retention, which can positively influence overall employee morale and retention strategies.

Next Steps

• Continued vesting of 179,691 stock options, with 25% vesting on February 2, 2027, and the remainder in 36 equal monthly installments thereafter.
• Continued vesting of 50,827 Restricted Stock Units (RSUs) in four successive equal annual installments over four years from February 2, 2026.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions, including a non-discretionary 'sell to cover' for tax purposes and new equity grants as part of executive compensation. These events are standard and do not provide new material information that would warrant a change in investment thesis. Therefore, a 'hold' recommendation is appropriate, maintaining current positions based on broader company fundamentals rather than these specific insider transactions.

Keywords

Allogene Therapeutics, ALLO, Form 4, Insider Trading, Stock Options, Restricted Stock Units, Equity Grant, Sell to Cover, Annie Yoshiyama, SVP Finance